Venetoclax + Rituximab for Mantle Cell Lymphoma

Overseen By Phirun Mindel

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Must not be taking: Warfarin, Live vaccines

Disqualifiers: Blastoid-variant, CNS involvement, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 12

Duration: 48 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a combination of two drugs, venetoclax and rituximab, can effectively treat mantle cell lymphoma without chemotherapy. The focus is on individuals over 60 who have been newly diagnosed with this type of cancer and have not yet started treatment. Participants must have a confirmed diagnosis of mantle cell lymphoma and require treatment as determined by their doctor. The goal is to assess if this drug combination can elicit a strong response in patients. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking warfarin, you cannot participate in the trial.

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research has shown that the combination of venetoclax and rituximab has been tested in several studies, primarily involving patients with certain blood cancers. These studies generally found that patients tolerate the combination well. Specifically, one study found that using venetoclax with rituximab had a manageable safety profile.

Some side effects were reported, but they were usually mild or moderate. Common issues included low blood cell counts and infections, which were treatable. This treatment has been used safely in patients with similar types of cancer, suggesting it could be a safe option for those with mantle cell lymphoma as well. However, discussing any concerns with healthcare providers before joining a trial is always important. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Venetoclax is unique for treating mantle cell lymphoma because it targets a protein called BCL-2, which helps cancer cells survive. Unlike standard treatments like chemotherapy, which attack all rapidly dividing cells, venetoclax specifically disrupts cancer cell survival without broadly affecting other cells. Researchers are excited because this targeted mechanism can lead to more effective treatment with potentially fewer side effects. Additionally, when combined with rituximab, venetoclax may enhance the immune system's ability to fight cancer, offering a promising new option for patients over 60 with this challenging condition.

What evidence suggests that venetoclax and rituximab might be an effective treatment for mantle cell lymphoma?

Research has shown that venetoclax combined with rituximab can effectively treat mantle cell lymphoma (MCL). In this trial, participants over 60 years old with previously untreated MCL will receive this combination. Studies have found that it leads to complete remission in over 60% of patients, meaning more than half had no detectable cancer after treatment. Venetoclax directly kills cancer cells, while rituximab helps the immune system find and attack them. This combination offers hope for significant, long-lasting results for people with MCL. ^{1 6 7 8 9}

Who Is on the Research Team?

Lode Swinnen, MD

Principal Investigator

Johns Hopkins School of Medicine

Are You a Good Fit for This Trial?

This trial is for people over 60 with a new diagnosis of mantle cell lymphoma who need treatment but haven't had any yet. They should be in fairly good health, able to perform daily activities, and have decent blood counts and organ function. Pregnant or breastfeeding women can't join, nor can those with certain types of the disease, uncontrolled infections, HIV, hepatitis B or C.

Inclusion Criteria

I am a woman who cannot become pregnant due to surgery, menopause, or a negative pregnancy test.

I am 60 years old or older.

I am using birth control as required.

Exclusion Criteria

My lymphoma is in the early stages (stage I or II).

I have an infection that isn't responding to treatment.

I am currently pregnant or breastfeeding.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive venetoclax and rituximab for up to 12 cycles of 4 weeks each. Dose adjustments based on response at cycles 4 and 8.

48 weeks

12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks

Extension

Participants achieving a CR may have long durations of response that continue after stopping venetoclax

Long-term

What Are the Treatments Tested in This Trial?

Interventions

• Venetoclax

Trial Overview The study tests Venetoclax tablets combined with Rituximab injections as an initial therapy for older patients with mantle cell lymphoma. It's an open-label phase II trial aiming to see if this drug combo works well without chemotherapy by measuring overall response rates using PET/CT scans.

How Is the Trial Designed?

Group I: venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma Experimental Treatment 1 Intervention

Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.

Venetoclax is already approved in United States, European Union for the following indications:

Approved in United States as Venclexta for:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Acute myeloid leukemia (AML)

Approved in European Union as Venclyxto for:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Acute myeloid leukemia (AML)

Who Is Running the Clinical Trial?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Lead Sponsor

Trials

578

Recruited

33,600+

AbbVie

Industry Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Published Research Related to This Trial

In a retrospective study of 34 adult patients with various types of non-Hodgkin lymphoma treated off-label with venetoclax, the overall response rate was 26%, indicating modest efficacy in heavily pretreated patients.

Adverse events occurred in 76% of patients, with higher incidence than reported in clinical trials, highlighting the need for further investigation into the safety and dosing strategies of venetoclax in real-world settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. Hughes, ME., Landsburg, DJ., Rubin, DJ., et al.[2020]

In a study involving 10 patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the addition of rituximab to venetoclax therapy resulted in a 50% response rate, with three patients achieving complete responses and two achieving partial responses.

The combination treatment was well tolerated, suggesting that adding rituximab after progression on venetoclax may provide a beneficial option for some patients with R/R CLL.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. Handunnetti, S., Anderson, MA., Roberts, AW., et al.[2022]

In a phase I trial involving 106 patients with various subtypes of non-Hodgkin lymphoma, venetoclax, a BCL-2 inhibitor, was found to be generally well tolerated, with a 44% overall response rate across different lymphoma types.

The study identified 1,200 mg as the recommended dose for future studies in follicular lymphoma and diffuse large B-cell lymphoma, while 800 mg was effective for mantle cell lymphoma, indicating varying efficacy based on lymphoma subtype.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Davids, MS., Roberts, AW., Seymour, JF., et al.[2018]

In a study of 323 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a daily dose of 400 mg of venetoclax resulted in a median progression-free survival (PFS) of 1.8 years.

The addition of 6 cycles of rituximab to venetoclax treatment significantly increased the median PFS to 3.9 years, demonstrating a synergistic effect that enhances treatment efficacy beyond increasing the venetoclax dose alone.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Freise, KJ., Jones, AK., Menon, RM., et al.[2018]

In a multicenter study of 28 patients with untreated mantle cell lymphoma (MCL), the combination of lenalidomide, rituximab, and venetoclax demonstrated a high overall response rate of 96% and a complete response rate of 86%, indicating strong efficacy for this treatment regimen.

The treatment was found to be safe, with no dose-limiting toxicities reported, although common side effects included neutropenia and thrombocytopenia, suggesting that this combination could be a promising option for patients who are ineligible for transplantation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Phillips, TJ., Bond, D., Takiar, R., et al.[2023]

Venetoclax is an effective oral treatment for relapsed or refractory chronic lymphocytic leukemia (CLL), showing durable responses and a manageable safety profile in clinical trials, including patients with poor prognostic factors.

In combination with rituximab, venetoclax significantly improved progression-free survival and achieved undetectable minimal residual disease compared to bendamustine plus rituximab, with benefits lasting for at least 36 months.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. Scott, LJ.[2020]

Venetoclax is a highly effective treatment for relapsed or refractory chronic lymphocytic leukemia (CLL), achieving response rates of about 80% in clinical trials involving 240 patients from 2011 to 2016.

While venetoclax has an acceptable safety profile, common side effects include neutropenia and diarrhea, and there is a risk of tumor lysis syndrome (TLS), which can be managed through careful dose ramp-up and patient education, leading to no reported TLS events in ongoing trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia . Brumbaugh Paradis, H., Alter, D., Llerandi, D.[2018]

Venetoclax is an oral medication that selectively inhibits the BCL-2 protein, which helps cancer cells survive, thereby restoring the ability of these malignant cells to undergo programmed cell death (apoptosis).

It has been approved in the USA for treating chronic lymphocytic leukaemia (CLL) in patients with a specific genetic marker (17p deletion) who have already undergone at least one prior therapy, and it is being studied for various other blood cancers and conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Venetoclax: First Global Approval. Deeks, ED.[2018]

In the phase III CLL14 trial, a 12-month treatment with venetoclax combined with obinutuzumab significantly improved progression-free survival and rates of undetectable minimal residual disease compared to traditional chemoimmunotherapy with chlorambucil and obinutuzumab in patients with untreated chronic lymphocytic leukaemia.

Venetoclax + obinutuzumab is a well-tolerated, chemotherapy-free treatment option for CLL, with manageable side effects like neutropenia, making it suitable for patients who cannot undergo intensive chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia. Blair, HA.[2021]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10320213/

A multicenter analysis of the outcomes with venetoclax in ... In high-risk patients with relapsed MCL, most of whom received prior BTKi, venetoclax resulted in ORR of 40% and median PFS of 3.7 months.

2. ashpublications.org ashpublications.org/blood/article/126/23/254/112989/A-Phase-1-Study-of-Venetoclax-ABT-199-GDC-0199

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199 ... We present updated data on the safety profile and efficacy as of June 10, 2015. ... Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas ...

3. aol.amegroups.org aol.amegroups.org/article/view/5134/html

Venetoclax for the treatment of mantle cell lymphoma - Lin This therapeutic combination has increased the rate of complete remissions to over 60% and provides a promising route to meaningful long-term ...

4. clinicaltrials.gov clinicaltrials.gov/study/NCT03710772

Ibrutinib, Rituximab, Venetoclax, and Combination ... Giving ibrutinib, rituximab, and venetoclax together with combination chemotherapy may work better in treating patients with mantle cell lymphoma. Detailed ...

5. nejm.org nejm.org/doi/full/10.1056/NEJMoa1715519

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell ... In a phase 1 study, venetoclax had greatest single-agent activity, among B-cell cancers, against chronic lymphocytic leukemia and mantle-cell ...

6. clinicaltrials.gov clinicaltrials.gov/study/NCT02055820

NCT02055820 | A Study Evaluating the Safety, Efficacy ... This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard ...

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6535706/

Update on the role of venetoclax and rituximab in the ... Initial phase I trials of venetoclax monotherapy confirmed its potent antitumor activity in vivo in patients with relapsed/refractory CLL. Single doses resulted ...

8. learningcenter.ehaweb.org learningcenter.ehaweb.org/eha/2015/20th/103125/andrew.w.roberts.venetoclax.(abt-199.gdc-0199).combined.with.rituximab.induces.html

VENETOCLAX (ABT-199 / GDC-0199) COMBINED WITH ... Single agent venetoclax induces responses in ~80% of pts with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). Pts ...

9. sciencedirect.com sciencedirect.com/science/article/pii/S0006497118472333

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) ... We present updated data on the safety profile and efficacy as of June 10, 2015. ... cell lymphoma (PMBCL). The median age was 68 (range: 25-86).